Literature DB >> 8905480

5-HT2 receptors are partially involved in the relationship between renin release and delta relative power.

G Brandenberger1, R Luthringer, G Muller, C Gronfier, N Schaltenbrand, J P Macher, A Muzet, M Follenius.   

Abstract

A strong relationship was previously described between the nocturnal oscillations of plasma renin activity (PRA) and the sleep cycles, with levels of PRA that increase during non rapid eye movement sleep and decrease during rapid eye movement sleep. This study was designed to determine whether ritanserin, a 5-hydroxytryptamine-2 (5-HT2) receptor antagonist known to increase slow wave sleep both in human and in animals and to decrease plasma renin activity response to serotonergic stimulation in the rat, would uncouple this relationship. Eight subjects underwent two randomized night studies after having received either placebo or 5 mg ritanserin administered in the morning. They were subjected to 8 hour polysomnography, including spectral analysis of the electroencephalogram and to continuous blood sampling. Blood was sampled from 2300 to 700h every 10 min and plasma renin activity (PRA) was measured by radioimmunoassay of angiotensin 1. The nocturnal profiles were analysed using the pulse detection program ULTRA. Ritanserin produced the expected increase in slow wave sleep (SWS) duration (132 +/- 10 min under ritanserin vs 72 +/- 9 min under placebo; p < 0.001) and a significant increase in delta relative power (69 +/- 2% under ritanserin vs 60 +/- 2% under placebo; p < 0.01). The mean overnight PRA levels had a tendency to decrease under ritanserin (1.66 +/- 0.34 ngAngl/ml per h under ritanserin vs 1.48 +/- 0.31 ngAngl/ml per h under placebo; p = 0.08). Individual PRA oscillations were preserved and remained strongly associated with delta power oscillations. PRA peak levels were similar in both experimental conditions, but the absolute amplitude of the oscillations was decreased under ritanserin (1.50 +/- 0.36 ngAngl/ml per h vs 1.04 +/- 0.14 ngAngl/ml per h; p < 0.05). These results demonstrate that ritanserin, at a dose that augments delta power, only weakly affects renin release, which suggests that 5-HT2 receptors are only partially involved in the processes coupling renin release and SWS and that other mechanisms probably control the sleep-associated variations in PRA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8905480     DOI: 10.1007/BF03349016

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  25 in total

1.  Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard.

Authors:  T Hori; Y Sugita; E Koga; S Shirakawa; K Inoue; S Uchida; H Kuwahara; M Kousaka; T Kobayashi; Y Tsuji; M Terashima; K Fukuda; N Fukuda
Journal:  Psychiatry Clin Neurosci       Date:  2001-06       Impact factor: 5.188

2.  Neuroendocrine evidence for denervation supersensitivity of serotonin receptors: effects of the 5-HT agonist RU 24969 on corticotropin, corticosterone, prolactin and renin secretion.

Authors:  L D Van de Kar; M Carnes; R J Maslowski; A M Bonadonna; P A Rittenhouse; K Kunimoto; R A Piechowski; C L Bethea
Journal:  J Pharmacol Exp Ther       Date:  1989-11       Impact factor: 4.030

Review 3.  Morphology, physiology, and molecular biology of renin secretion.

Authors:  E Hackenthal; M Paul; D Ganten; R Taugner
Journal:  Physiol Rev       Date:  1990-10       Impact factor: 37.312

4.  A dose-response study examining the effects of ritanserin on human slow wave sleep.

Authors:  C Idzikowski; F J Mills; R J James
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

5.  5-Hydroxytryptamine-2 antagonist increases human slow wave sleep.

Authors:  C Idzikowski; F J Mills; R Glennard
Journal:  Brain Res       Date:  1986-07-16       Impact factor: 3.252

6.  Twenty-four-hour profiles of plasma renin activity in relation to the sleep-wake cycle.

Authors:  G Brandenberger; M Follenius; B Goichot; J Saini; K Spiegel; J Ehrhart; C Simon
Journal:  J Hypertens       Date:  1994-03       Impact factor: 4.844

7.  Central stimulation of renin secretion through serotonergic, noncardiovascular mechanisms.

Authors:  P A Rittenhouse; E A Bakkum; A D Levy; Q Li; J M Yracheta; K Kunimoto; L D van de Kar
Journal:  Neuroendocrinology       Date:  1994-08       Impact factor: 4.914

8.  Effects of repeated ritanserin on middle-aged poor sleepers.

Authors:  K Adam; I Oswald
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

9.  Evidence that the serotonin agonist, DOI, increases renin secretion and blood pressure through both central and peripheral 5-HT2 receptors.

Authors:  P A Rittenhouse; E A Bakkum; L D Van de Kar
Journal:  J Pharmacol Exp Ther       Date:  1991-10       Impact factor: 4.030

10.  Effects of ritanserin on sleep disturbances of dysthymic patients.

Authors:  T Paiva; F Arriaga; A Wauquier; E Lara; R Largo; J N Leitao
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

View more
  1 in total

1.  Effects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cortex of conscious rats; antagonism by clozapine, and antagonists of AMPA-, alpha(1)- and 5-HT(2A)-receptors.

Authors:  Claude Sebban; Brigitte Tesolin-Decros; Jorge Ciprian-Ollivier; Laurent Perret; Michael Spedding
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.